SecBot SecBot
6-K ·Filed Sep 29, 2026

MCTA

Charming Medical Ltd
NEUTRAL
Impact 2/10
Horizonweeks Processed28d 3h ago SEC0001213900-26-104311
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the EGM outcome on October 23 for formal approval; if passed, the simplified capital structure removes the overhang of unissued Class B shares but has no immediate financial or operational read-through.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
MCTA ▲ 0.00% at T+5d
NEUTRAL call 0.00% · α vs SPY -1.95% · entry $29.36 → $29.36
Next anchor: T+20d due 3h ago
Latest observation: T+18 0.00% FF3 residual α
Entry = T+0 close
Sep 29, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.21%
$29.36
settled 27d ago
T+5d
0.00%
call 0.00% · α -1.95%
$29.36
settled 21d ago
T+20d
Pending
due 3h ago
T+60d
Pending
in 8w

Price Chart

Loading chart...

Executive Summary

Charming Medical Ltd is holding an Extraordinary General Meeting on October 23, 2026, to vote on cancelling all 15,000,000 authorized but unissued Class B shares and eliminating the dual-class share structure, transitioning to a single-class share structure with one vote per share. This is a routine governance simplification — no Class B shares are currently outstanding, no shareholder dilution or financial impact is involved, and the board unanimously recommends approval.

Key Facts

  • EGM scheduled for October 23, 2026 (10:30 a.m. HKT / 10:30 p.m. ET October 22)
  • Proposal to cancel 15,000,000 authorized but unissued Class B shares, reducing total authorized shares from 75,000,000 to 60,000,000 Class A shares
  • All 2,000,000 previously issued Class B shares have already been surrendered for no consideration and cancelled
  • As of September 25, 2026 record date, 15,178,000 Class A shares issued and outstanding; no Class B shares outstanding
  • Post-cancellation, 44,822,000 authorized but unissued shares would remain available for future issuance
  • Proposal Two adopts amended articles to remove the dual-class structure and prohibit future creation of multi-vote shares
  • Board unanimously recommends voting FOR all three proposals

Financial Impact

No financial impact — cancellation involves no issuance, repurchase, redemption, dilution, or payment to shareholders

Risk Factors

  • No material risks identified — this is a routine governance simplification with no financial consequences

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-104311
Document: ea030667101ex99-2.htm0001213900-26-104311
Document: ea0306671-6k_charming.htm0001213900-26-104311
Document: 0001213900-26-104311-index-headers.html0001213900-26-104311
Document: 0001213900-26-104311-index.html0001213900-26-104311
Document: 0001213900-26-104311.txt0001213900-26-104311
2 reports for MCTA
Performance horizon
Filters
Rows
Reports for MCTA — sortable, filterable
TypeNow
Sep 29, 2026
28d ago
6-K
NEUTRAL ★ 2/10
$29.36awaiting T+20—$29.35 (−0.00%)
Mar 27, 2026
30w ago
6-K
NEUTRAL ★ 3/10
$29.36 $29.36· 0.00%▼ −12.74%$29.35 (−0.00%)
Showing 2 of 2

US Market Status

Market Open — Closes in 5h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 29, 2026